Kazia Therapeutics🔒 SSL Verified
Live Data Status: |E-commerce & Retail
Welcome to the detailed analysis for kaziatherapeutics.com. This domain is officially recognized as Kazia Therapeutics (KZIA). According to their official web presence, their primary focus is: "Detailed SEO and authority metrics for kaziatherapeutics.com. Kaziatherapeutics currently holds an estimated domain authority score of 70/100 in the .COM namespace based on our global index mapping.".
Table of Contents
- Tech Stack
- Custom Built / Unknown
- Link Profile
- Internal Pages: 46Outbound Links: 17
- Localization
- en
6-Month Traffic Trend Estimate
M1
M2
M3
M4
M5
M6
Estimated Market Value
$3,825
Based on domain age, authority, and keyword relevance.
TLD Availability Risk
- kaziatherapeutics.comTaken
- kaziatherapeutics.netTaken
- kaziatherapeutics.orgTaken
- kaziatherapeutics.ioTaken
- kaziatherapeutics.coAvailable
- kaziatherapeutics.aiAvailable
Official Contact & Profiles
Content Snippets from kaziatherapeutics.com
"Kazia Therapeutics is a clinical-stage oncology company focused on developing therapies for aggressive solid tumors. We are advancing a new paradigm in cancer treatment by leveraging precision pathway inhibition to reprogram cancer biology, restore anti-tumor immunity, and overcome treatment resistance."
"We are advancing next-generation therapeutics that target multiple layers of cancer and immune control. Our multi-modal platforms targeting tumor dormancy are designed to overcome metastases, recurrence, and resistance in aggressive and immunotherapy-refractory cancers."
"Paxalisib is a brain-penetrant, oral, once-daily small molecule that acts as a dual PI3K/mTOR inhibitor, targeting key pathways that drive tumor growth and survival. Beyond its core kinase inhibition, it also influences tumor epigenetic regulation, transcriptional state, and the immune microenvironment."
"The PD-L1 Protein Degrader Platform represents a first-in-class strategy to target unique tumor-specific nuclear PD-L1 post-translational forms not found in healthy cells. This novel target was identified through a reverse-translation liquid-biopsy profiling AI platform. Our lead asset, NDL2, is designed to selectively engage tumor-associated nuclear PD-L1 protein while sparing normal cellular PD-L1 and extending beyond the reach of traditional antibody-based approaches."
Key Topics & Focus Areas for kaziatherapeutics.com:
Beyond Inhibition
Complementary Layers of Cancer Control
A Pipeline Powering Precision Therapies
Targeted Technology that Transforms Patient Outcomes
Latest News
Email Alerts
By comparing kaziatherapeutics.com to other leading websites in its niche, marketers and researchers can identify key traffic sources and growth opportunities. Explore our related resources below to find websites similar to kaziatherapeutics.com.
Frequently Asked Questions
Is kaziatherapeutics.com a safe and secure website?
Yes, according to our latest analysis, we detected a valid SSL certificate ensuring a secure connection.
What is the authority score of kaziatherapeutics.com?
As of September 19, 2026, kaziatherapeutics.com holds an estimated domain authority score of 75/100 based on our VisitRank tracking algorithms.
What are the top alternatives to kaziatherapeutics.com?
You can find the best alternatives and similar sites to kaziatherapeutics.com in our explore section, which includes competitors in the E-commerce & Retail sector.
Data Sources & Methodology: DNS telemetry and routing records are resolved via live root servers. Market valuation estimates are computed algorithmically based on proprietary historical indexation multiples and standardized digital asset appraisal methodologies.
Common Misspellings & Typo Domains for kaziatherapeutics.com:
kzaiatherapeutics.comkaiatherapeutics.comkaaziatherapeutics.comkeziatherapeutics.comkazoatherapeutics.comkazietherapeutics.comkaziatharapeutics.comkaziatherepeutics.comkaziatherapautics.comkaziatherapeotics.com